{"id":14206,"date":"2009-10-27T10:30:28","date_gmt":"2009-10-27T09:30:28","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=14206"},"modified":"2021-09-13T10:33:08","modified_gmt":"2021-09-13T08:33:08","slug":"puente-j-calderero-v-garcia-muro-x-trigo-jm-castro-aj-martin-escudero-v-yebenes-m-casado-ma-3","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/puente-j-calderero-v-garcia-muro-x-trigo-jm-castro-aj-martin-escudero-v-yebenes-m-casado-ma-3\/","title":{"rendered":"Puente J, Calderero V, Garc\u00eda-Muro X, Trigo JM, Castro AJ, Mart\u00edn-Escudero V, Y\u00e9benes M, Casado MA"},"content":{"rendered":"<div class=\"col80\">\n<p class=\"miniatura_foto\" style=\"text-align: justify;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-14157 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/09\/ISPOR.jpg\" alt=\"\" width=\"120\" height=\"120\" \/>Puente J, Calderero V, Garc\u00eda-Muro X, Trigo JM, Castro AJ, Mart\u00edn-Escudero V, Y\u00e9benes M, Casado MA<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col80p\">\n<h6 style=\"text-align: justify;\">Cost of managing adverse events in the treatment of first line metastasic renal cell carcinoma: bevacizumab + interferon alpha-2a compared with sunitinib in Spain<\/h6>\n<h6 style=\"text-align: justify;\"><strong>12th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Paris, France. 24-27 oct 2009<\/strong><\/h6>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Puente J, Calderero V, Garc\u00eda-Muro X, Trigo JM, Castro AJ, Mart\u00edn-Escudero V, Y\u00e9benes M, Casado MA &nbsp; &nbsp; Cost of managing adverse events in the treatment of first line metastasic renal cell carcinoma: bevacizumab + interferon alpha-2a compared with sunitinib in Spain 12th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Paris,&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/puente-j-calderero-v-garcia-muro-x-trigo-jm-castro-aj-martin-escudero-v-yebenes-m-casado-ma-3\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[937,928,246],"tags":[],"class_list":["post-14206","post","type-post","status-publish","format-quote","hentry","category-amc-ac-tipo-de-proyecto","category-oncologia","category-international-society-of-pharmacoeconomics-and-outcomes-research","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14206"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=14206"}],"version-history":[{"count":3,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14206\/revisions"}],"predecessor-version":[{"id":14209,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14206\/revisions\/14209"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=14206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=14206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=14206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}